Literature DB >> 12666134

Acquired von Willebrand's syndrome: a single institution experience.

Shaji Kumar1, Rajiv K Pruthi, William L Nichols.   

Abstract

Acquired von Willebrand's disease or syndrome (AVWS) is a rare bleeding disorder distinguished from congenital von Willebrand's disease by age at presentation and absence of personal and family history of bleeding disorders. We report on 22 patients with AVWS seen over 25 years. Mean age at diagnosis was 61.3 years (range 38-86 years); most patients had a spontaneous or a post-operative hemorrhage at presentation. Gastrointestinal bleeding and epistaxis were the most common spontaneous symptoms. Bleeding time was prolonged in most patients, associated with marked reductions in plasma von Willebrand factor antigen and ristocetin cofactor activity. Plasma VWF multimer distribution was normal (type 1 pattern) in 5 patients, indeterminate (no multimers detectable) in 6 patients (type 3 pattern), and abnormal (decreased higher-molecular-weight multimers, type 2 pattern) in 11 patients. None of 17 patients tested had an inhibitor of ristocetin cofactor activity. An underlying malignant or benign hematologic disease was found in 18 patients, and 1 patient had Crohn's disease. Desmopressin was effective in only half the patients so treated, but all patients responded to treatment with VWF-containing concentrates. Resolution of AVWS occurred with therapy of lymphoma (1 patient) and chronic lymphocytic leukemia (1 patient). Sixteen patients were alive at last follow-up; no deaths were related to bleeding. AVWS may be more prevalent than has been appreciated; we estimate up to 0.04%. Awareness of the existence of AVWS is essential for diagnosis and appropriate management. Therapy of associated diseases may improve the bleeding disorder. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12666134     DOI: 10.1002/ajh.10298

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.

Authors:  Massimo Franchini; Giancarlo Castaman; Antonio Coppola; Cristina Santoro; Ezio Zanon; Giovanni Di Minno; Massimo Morfini; Elena Santagostino; Angiola Rocino
Journal:  Blood Transfus       Date:  2015-06-24       Impact factor: 3.443

2.  Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy : Breaking a dangerous bond.

Authors:  Georg Jeryczynski; Hermine Agis; Sabine Eichinger-Hasenauer; Maria Theresa Krauth
Journal:  Wien Klin Wochenschr       Date:  2022-03-19       Impact factor: 2.275

3.  Spontaneous retroperitoneal hemorrhage in a patient with prolymphocytic transformation of chronic lymphocytic leukemia.

Authors:  Gwynivere A Davies; Alejandro Lazo-Langner; Michael Shkrum; Leonard Minuk
Journal:  Case Rep Hematol       Date:  2013-08-19

4.  Successful management of severe refractory acquired immune bleeding disorder: Prior to insisting surgery.

Authors:  Hassan Al-Jafar; H Al-Barjas; Raed A Hashem; Thanaa M K Refaii; Ahmad M AlSaeed
Journal:  Int J Surg Case Rep       Date:  2014-10-31

5.  Acquired Von Willebrand's Syndrome in Systemic Lupus Erythematosus.

Authors:  Sara Taveras Alam; Karenza Alexis; Ashwin Sridharan; Marianna Strakhan; Tarek Elrafei; Richard J Gralla; Louis J Reed
Journal:  Case Rep Hematol       Date:  2014-12-07

6.  Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome: A Case of a Patient With Membranous Nephropathy.

Authors:  Taro Sugase; Tetsu Akimoto; Takaaki Kimura; Takashi Yagisawa; Eiji Kusano; Daisuke Nagata
Journal:  Clin Med Insights Case Rep       Date:  2018-03-13

Review 7.  Acquired von Willebrand syndrome: focused for hematologists.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2020-06-18       Impact factor: 9.941

8.  Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy.

Authors:  Allen Green; Yu-Min P Shen; Andrew T Nelson; Ravi Sarode; Ibrahim F Ibrahim; Jing Cao; Sajjad Afraz; Sean G Yates
Journal:  Ann Hematol       Date:  2022-10-04       Impact factor: 4.030

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.